About 4 results found for searched term "Anti-human PD-1 mAb" (0.137 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M11385 | Anti-human PD-1 mAb | Cytokines and Growth Factors |
| Biological activity: PD-1 is mainly expressed in activated T cells and B cells, and its function is to inhibit cell activation, which is a normal self-stabilizing mechanism of the immune system. Because excessive T/B cell activation can cause autoimmune diseases, PD-1 is a talisman of our body. | ||
| M24853 | Toripalimab | PD-1/PD-L1 |
| Toripalimab is the first domestic anti-tumor PD-1 antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma. | ||
| M24923 | Envafolimab | PD-1/PD-L1 |
| ASC 22; KN 035 | ||
| Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25 nM. Envafolimab has the potential for the research of solid tumors. | ||
| M25141 | Iparomlimab | PD-1/PD-L1 |
| Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
